Current Report Filing (8-k)
07 May 2021 - 8:10PM
Edgar (US Regulatory)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of The Securities
Exchange Act of 1934
Date of Report (Date of Earliest Event Reported):
May 5, 2021
Summit Therapeutics Inc.
|
(Exact Name of Registrant as Specified in Its Charter)
|
|
|
|
Delaware
|
001-36866
|
37-1979717
|
(State or Other Jurisdiction
of Incorporation)
|
(Commission
File Number)
|
(IRS Employer
Identification No.)
|
|
|
|
One Broadway, 14th Floor, Cambridge, MA
|
02142
|
(Address of Principal Executive Offices)
|
(Zip Code)
|
Registrant’s Telephone Number, Including Area
Code: 617-514-7149
Not Applicable
|
(Former Name or Former Address, If Changed Since Last Report)
|
Check the appropriate box below if the Form 8-K filing is intended
to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction
A.2. below):
☐ Written communications
pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐ Soliciting material
pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐ Pre-commencement
communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐ Pre-commencement communications pursuant to Rule 13e-4(c)
under the Exchange Act (17 CFR 240.13e-4(c))
Securities registered pursuant to Section 12(b) of the Act:
Title of Each Class
|
Trading Symbol(s)
|
Name of Each Exchange on Which Registered
|
Common stock, $0.01 par value per share
|
SMMT
|
The Nasdaq Stock Market LLC
|
Indicate by check mark whether the registrant is an emerging
growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities
Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company ☐
If an emerging growth company, indicate by check mark if
the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting
standards provided pursuant to Section 13(a) of the Exchange Act. ☐
On May 5, 2021, Summit Therapeutics Inc. (the “Company”)
issued a press release advising the Company’s stockholders of the upcoming deadline on May 10, 2021 at 5:00 p.m. Eastern Daylight
Time to subscribe for shares of the Company’s common stock, par value $0.01 (the “Common Stock”) in the Company’s
previously announced rights offering. In addition, Mr. Robert W. Duggan, the Company’s Chairman, Chief Executive Officer, and majority
shareholder, has advised the Board of Directors of the Company that, in addition to exercising all of his basic subscription rights, he
will exercise his oversubscription rights to purchase all additional shares of Common Stock that remain unsubscribed at the expiration
of the rights offering.
A copy of the press release is attached hereto as Exhibit
99.1 and is incorporated herein by reference.
|
Item 9.01
|
Financial Statements and Exhibits.
|
(d) Exhibits
SIGNATURE
Pursuant to the requirements of the Securities
Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.
|
SUMMIT THERAPEUTICS INC.
|
|
|
|
|
Date: May 6, 2021
|
By:
|
/s/ Michael Donaldson
|
|
|
Michael Donaldson
|
|
|
Chief Financial Officer
|
Summit Therapeutics (NASDAQ:SMMT)
Historical Stock Chart
From Jun 2024 to Jul 2024
Summit Therapeutics (NASDAQ:SMMT)
Historical Stock Chart
From Jul 2023 to Jul 2024